A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
Status:
Active, not recruiting
Trial end date:
2023-12-16
Target enrollment:
Participant gender:
Summary
This randomized, parallel group, double-blind, placebo controlled study will evaluate the
efficacy and safety of ocrelizumab in participants with primary progressive multiple
sclerosis. Eligible participants will be randomized 2 : 1 to receive either ocrelizumab or
placebo. The blinded treatment period will be at least 120 weeks, followed by an Open Label
Extension (OLE) treatment for participants in both groups who in the opinion of the
investigator could benefit from further or newly initiated ocrelizumab treatment. Unless
terminated early, all participants may continue their treatment with open-label ocrelizumab
until 31 December 2020.